Last reviewed · How we verify
vitagen plus hyruan — Competitive Intelligence Brief
marketed
Viscosupplement / Joint lubricant
Hyaluronic acid receptor (CD44); joint synovial fluid
Orthopedics / Rheumatology
Small molecule
Live · refreshed every 30 min
Target snapshot
vitagen plus hyruan (vitagen plus hyruan) — Taipei Medical University. Vitagen Plus Hyruan is a combination product that delivers hyaluronic acid and bioactive compounds to support joint lubrication and tissue hydration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| vitagen plus hyruan TARGET | vitagen plus hyruan | Taipei Medical University | marketed | Viscosupplement / Joint lubricant | Hyaluronic acid receptor (CD44); joint synovial fluid |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Viscosupplement / Joint lubricant class)
- Taipei Medical University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- vitagen plus hyruan CI watch — RSS
- vitagen plus hyruan CI watch — Atom
- vitagen plus hyruan CI watch — JSON
- vitagen plus hyruan alone — RSS
- Whole Viscosupplement / Joint lubricant class — RSS
Cite this brief
Drug Landscape (2026). vitagen plus hyruan — Competitive Intelligence Brief. https://druglandscape.com/ci/vitagen-plus-hyruan. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab